Evidence map›Paper›PMID 28900611›Full record

ArticleAdvanced biomedical research2017

The Protective Effect of L-arginine in Cisplatin-induced Nephrotoxicity in Streptozotocin-induced Diabetic Rats.

Fatemeh Gharibi, Nepton Soltani, Maryam Maleki, Ardeshir Talebi, Masoumeh Nasiri, Soheyla Shirdavani, Mehdi Nematbakhsh

Open access · goldAbstract read
In one paragraph

Article in Advanced biomedical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fatemeh GharibiWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Nepton SoltaniMolecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Maryam MalekiWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Ardeshir TalebiClinical Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Masoumeh NasiriWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Soheyla ShirdavaniWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mehdi NematbakhshWater and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin (CP) is accompanied with a nephrotoxicity. L-arginine (LA) plays an important role in the regulation of renal function. The present study was designed to investigate the protective role of LA supplementation in CP-induced nephrotoxicity in a diabetic rat's model. MATERIALS AND

methodsSixteen adult female and male Wistar rats were used and they received a single dose of streptozotocin (STZ) (60 mg/kg i.p.). Diabetic female and male rats were arranged as groups 1-5 and groups 6-10, respectively. Groups 1 and 6 (LA groups) received LA alone. Groups 2 and 7 (CP groups) received CP alone. Groups 3 and 8 (CP + LA [PT] groups) received LA as prophylaxis and then treated with LA and CP. Groups 4 and 9 (CP + LA [T] groups) were treated with LA and CP simultaneously. Groups 5 and 10 (CP + LA [P] groups) received LA as prophylaxis and then treated with CP.

resultsThe serum creatinine (Cr) level of males in Groups 8 and 9 was significantly increased when compared with LA and CP (

conclusionOur findings indicate that administration of LA in female and male rats has no protective effect on the severity of nephrotoxicity induced by CP in diabetic rats.

Indexed as

CisplatindiabetesL-argininenephrotoxicityrat

Identifiers

PMID28900611
PMCPMC5583628
OpenAlexW2749482663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.